ArticleBJUI compass2025
Perioperative chemotherapy use and related outcomes in muscle-invasive bladder cancer in Australia.
Article in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of body mass index on outcomes after radical cystectomy: A retrospective Australian cohort study.BJUI compass · 2026Article
- Perioperative chemotherapy use and related outcomes in muscle-invasive bladder cancer in Australia.BJUI compass · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To explore Australian data on perioperative chemotherapy use and associated outcomes in muscle-invasive bladder cancer (MIBC). Subjects and Methods: An observational study of patients with MIBC treated with neoadjuvant chemotherapy, adjuvant chemotherapy or surgery alone was conducted using data from BLADDA, a multicentre Australian urothelial cancer registry. Pathological response to neoadjuvant chemotherapy and its effect on event-free survival (EFS) and overall survival (OS) were determined. EFS and OS in patients who underwent neoadjuvant chemotherapy, adjuvant chemotherapy or surgery alone were compared using univariate and multivariable proportional hazards regression. Results: From 2018 to 2024, 259 patients enrolled in the BLADDA registry met inclusion criteria, of which 45% received neoadjuvant chemotherapy, 23% received adjuvant chemotherapy, 1.2% received both neoadjuvant and adjuvant chemotherapy and 31% underwent surgery only. The proportion of patients treated with neoadjuvant chemotherapy increased over time. A total of 21 of 67 (31%) evaluable subjects achieved a pathological complete response, which was associated with improved EFS and OS. Excluding patients who received both neoadjuvant and adjuvant chemotherapy, the EFS hazard ratio (HR) was 0.43 (95% confidence interval [CI] 0.29-0.65, p < 0.001) for neoadjuvant chemotherapy and 0.59 (95% CI 0.38-0.94, p = 0.03) for adjuvant chemotherapy compared to surgery alone. Neoadjuvant chemotherapy was associated with prolonged OS in the univariate analysis (HR 0.43, 95% CI 0.26-0.73, p = 0.002) but not in the multivariable analysis (HR 0.59, 95% CI 0.32-1.08, p = 0.09). OS was not improved with adjuvant chemotherapy (unadjusted HR 0.76, 95% CI 0.44-1.31, p = 0.3; adjusted HR 0.86, 95% CI 0.46-1.60, p = 0.6). Conclusion: Neoadjuvant chemotherapy use for MIBC in Australia has increased over the past decade, but it remains underutilised. This has important implications as perioperative chemo-immunotherapy emerges as a standard of care. Although a clear impact on survival in the overall population was not observed, this was potentially due to the limited sample size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.